Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Aileron Therapeutics (NASDAQ: ALRN), a biopharmaceutical company focused on developing first-in-class medicines for orphan pulmonary and fibrosis indications, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's President and CEO, Brian Windsor, Ph.D., is scheduled to present on Tuesday, August 13, 2024, at 4:00 p.m. EDT in Boston, MA.
Investors and interested parties can access a live webcast of the presentation through Aileron's investor relations website. The webcast replay will remain available for 90 days following the event, providing an opportunity for those unable to attend the live presentation to catch up on Aileron's latest developments and future plans.
Aileron Therapeutics (NASDAQ: ALRN), una compagnia biofarmaceutica focalizzata nello sviluppo di farmaci di nuova generazione per indicazioni orfane nel campo polmonare e della fibrosi, ha annunciato la sua partecipazione alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity. Il Presidente e CEO della società, Brian Windsor, Ph.D., è programmato per presentare martedì 13 agosto 2024, alle 16:00 EDT a Boston, MA.
Investitori e parti interessate possono accedere a un streaming live della presentazione tramite il sito web delle relazioni con gli investitori di Aileron. La registrazione del webcast rimarrà disponibile per 90 giorni dopo l'evento, offrendo così a chi non può partecipare alla presentazione dal vivo l'opportunità di aggiornarsi sugli ultimi sviluppi e piani futuri di Aileron.
Aileron Therapeutics (NASDAQ: ALRN), una compañía biofarmacéutica enfocada en desarrollar medicamentos de primera clase para indicaciones huérfanas en el ámbito pulmonar y de fibrosis, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. El Presidente y CEO de la compañía, Brian Windsor, Ph.D., está programado para presentar el martes 13 de agosto de 2024, a las 4:00 p.m. EDT en Boston, MA.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través del sitio web de relaciones con inversores de Aileron. La repetición de la transmisión estará disponible durante 90 días después del evento, brindando la oportunidad a quienes no puedan asistir a la presentación en vivo de mantenerse al día sobre los últimos desarrollos y planes futuros de Aileron.
Aileron Therapeutics (NASDAQ: ALRN)는 고아 폐 및 섬유증 관련 백신을 개발하는 데 중점을 둔 생물 제약 회사로, Canaccord Genuity 제44회 연례 성장 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 회장 겸 CEO인 Brian Windsor, Ph.D.는 2024년 8월 13일 화요일 오후 4시 EDT에 매사추세스주 보스턴에서 발표할 예정입니다.
투자자와 관심 있는 분들은 Aileron의 투자자 관계 웹사이트를 통해 실시간 웨비나에 접속할 수 있습니다. 웨비나 재방송은 행사 후 90일 동안 이용할 수 있어, 실시간 발표에 참여할 수 없는 분들이 Aileron의 최신 개발과 향후 계획에 대한 정보를 얻을 수 있는 기회를 제공합니다.
Aileron Therapeutics (NASDAQ: ALRN), une société biopharmaceutique spécialisée dans le développement de médicaments de première classe pour des indications orphelines en matière pulmonaire et de fibrose, a annoncé sa participation à la 44e Conférence Annuelle sur la Croissance de Canaccord Genuity. Le Président et CEO de la société, Brian Windsor, Ph.D., doit faire sa présentation le mardi 13 août 2024, à 16h00 EDT à Boston, MA.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via le site des relations investisseurs d'Aileron. La rediffusion du webinaire sera disponible pendant 90 jours après l'événement, offrant ainsi la possibilité à ceux qui ne peuvent pas assister à la présentation en direct de se tenir au courant des derniers développements et des projets futurs d'Aileron.
Aileron Therapeutics (NASDAQ: ALRN), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung erstklassiger Medikamente für seltene pulmonale und fibrotische Indikationen konzentriert, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity angekündigt. Der Präsident und CEO des Unternehmens, Brian Windsor, Ph.D., wird am Dienstag, den 13. August 2024 um 16:00 Uhr EDT in Boston, MA, präsentieren.
Investoren und interessierte Parteien können über die Investor-Relations-Website von Aileron auf ein Live-Webcast der Präsentation zugreifen. Die Wiederholung des Webcasts wird für 90 Tage nach der Veranstaltung verfügbar sein und bietet somit eine Gelegenheit für diejenigen, die an der Live-Präsentation nicht teilnehmen können, sich über die neuesten Entwicklungen und zukünftigen Pläne von Aileron zu informieren.
- None.
- None.
A live webcast of the event can be accessed at https://investors.aileronrx.com/events-presentations/investor-events. A replay of the webcast will be available for 90 days following the presentation.
About Aileron Therapeutics
Aileron Therapeutics, Inc. is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis. Aileron's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.
Investor Relations & Media Contact:
Argot Partners
aileron@argotpartners.com
212-600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/aileron-therapeutics-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-302208743.html
SOURCE Aileron Therapeutics, Inc.
FAQ
When is Aileron Therapeutics (ALRN) presenting at the Canaccord Genuity 44th Annual Growth Conference?
Who will be presenting for Aileron Therapeutics (ALRN) at the Canaccord Genuity conference?
How can investors access Aileron Therapeutics' (ALRN) presentation at the Canaccord Genuity conference?
How long will the replay of Aileron Therapeutics' (ALRN) presentation be available?
What is the focus of Aileron Therapeutics' (ALRN) drug development pipeline?
